|Test Method Number:||TM2008-05 (EU)|
|Short Name of TM:||hCLAT|
|Submission received on:||Monday, December 15, 2008|
|Responsible Organisation:||EURL ECVAM - European Union|
|Stage of Submission:||Assessment Finalised|
|Stage of Validation:||Finalised|
|Stage of Peer-review:||Finalised|
|Stage of Recommendation:||Published|
|Stage of Regulatory acceptance/Standards:||Published|
|General Comments:||Test Guideline has been adopted as TG442E in July 2016|
The h-CLAT quantifies in vitro changes in the expression of the CD86 and CD54 membrane phenotypic markers in a human monocytic leukemia cell line (THP-1 cells).
THP-1 cells are monocyte-derived cells that have shown to produce DC-like responses following exposure to skin sensitising chemicals (e.g. upregulation of surface markes (e.g. CD86 and CD54) and cytokine production (e.g. TNF-α).
The CD86 (a co-stimulatory molecule) and the CD54 (an adhesion molecule) are upregulated in activated Dendritic Cells (DC) and play a critical role in DC presentation of antigens to T cells (T-cell priming).
By studying the potential of test chemicals to up-regulate markers of DC activation, the h-CLAT generates information addressing key event 3 (dendritic cell activation) of the skin sensitization Adverse Outcome Pathway.
|In progress||Submission||Show status|
|In progress||Validation||Show status|
|In progress||Peer-review||Show status|
|In progress||Recommendation||Show status|
|In progress||Regulatory acceptance/Standards||Show status|